A Phase 1/2 interventional study of BDB-001 Injection and Placebo in Hidradenitis Suppurativa, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Hidradenitis Suppurativa with a site in China — 13 open to participants now, 17 under way, 2 of them phase 3. Hidradenitis Suppurativa · China.
Among the 22 studies in Hidradenitis Suppurativa with a site in China, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 1/2, and was the 1st registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →13 of the 22 studies in Hidradenitis Suppurativa with a site in China are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–45 · Healthy volunteers
Sanofi · Sites in China, United States, Argentina and 12 more countries
Ages 18+
Sanofi · Sites in China, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 3 · Phase 4 3
First in 2020; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 76 across the 18 interventional studies, 65 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Staidson (Beijing) Biopharmaceuticals Co., Ltd has 2 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
8 of the studies in Hidradenitis Suppurativa with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT07261072Peking Union Medical CollegeComparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS | 2026-11-30 |
| NCT07755670Second Xiangya Hospital of Central South UniversityExploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI | 2027-01 |
| NCT07244263TakedaA Study of Zasocitinib in Adults With Hidradenitis Suppurativa | 2027-02-05 |
| NCT07170917SanofiBrivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | 2027-02-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 22 studies in Hidradenitis Suppurativa with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BDB-001 Injection · Drug: Placebo
Drug: BDB-001 Injection · Drug: Placebo
Drug: Placebo
Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Multiple IV infusions of Placebo Injection diluted in sodium chloride
Multiple IV infusions of Placebo Injection diluted in sodium chloride
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients.
Time frame: Week 8
Number of Participants developing anti-BDB-001 antibodies.
Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients.
Time frame: Week 8
Area under the plasma concentration versus time curve (AUC) of BDB-001 Assessment of pharmacokinetic parameters.
To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.
Time frame: Week 8
Peak Plasma Concentration (Cmax) of BDB-001and time to reach Cmax Assessment of pharmacokinetic parameters.
To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.
Time frame: Week 8
Minimal Plasma Concentration (Cmin) of BDB-001 Assessment of pharmacokinetic parameters.
To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.
Time frame: Week 8
Terminal phase half-life Assessment of pharmacokinetic parameters.
To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.
Time frame: Week 8
Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point
The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group),IHS4 Score=(Nodule Count) + (Abscess Count\*2) + (Draining Tunnel Count \*4). IHS4 score uses a range grades: Mild= 0-3; Moderate=4-10; Severe ≥11.
Time frame: From Day 0 until Day 56
Change in modified Sartorius Score (mSS) from Day 0 by time point
The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.
Time frame: From Day 0 until Day 56
Change in Hidradenitis Suppurativa Clinical Response (HiSCR) from Day 0 by time point
The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.
Time frame: From Day 0 until Day 56
Change in Hidradenitis suppurativa-Physician Global Assessment (HS-PGA) score from Day 0 by time point
Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)classifies patients' severity into six categories:clear, minimal, mild, moderate, severe, and very severe, based on the number and quality of inflammatory lesions.
Time frame: From Day 0 until Day 56
Changes of active lesions (number of inflammatory nodules, abscesses, fistulas, and abscess overflow score) from Day 0 by time point
Time frame: From Day 0 until Day 56
Change in Dermatology Life Quality Index (DLQI) score from Day 0 by time point
A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.
Time frame: From Day 0 until Day 56
Changes in Pain VAS score from Day 0 by time point
Pain VAS:This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the VAS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome.
Time frame: From Day 0 until Day 56
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Jul 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BDB001
Staidson (Beijing) Biopharmaceuticals Co., Ltd →